用去纤苷可能会产生什么不良反应？

Defibrotide (defiteli) is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects. Defibrotide can also reduce the expression of cell adhesion molecules on the surface of endothelial cells, thereby reducing the adhesion of leukocytes to vascular endothelial cells and reducing the inflammatory damage of endothelial cells.

In addition, defibrotide (defiteli) can also promote the release of prostaglandin I2 (PGI2) and prostaglandin E2 (PGE2), thereby causing blood vessel dilation, inhibiting platelet aggregation, and reducing ischemic damage. Studies have shown that defibrotide can significantly increase the expression of thrombin regulatory protein (TM) and tissue factor pathway inhibitors to produce anticoagulant effects.

No matter what kind of drug it is, some adverse reactions will occur after long-term use, and defibrotide is no exception.

The most common adverse reactions (incidence ≥10% and independently causal) with defibrotide (defiteli) treatment are hypotension, diarrhea, vomiting, nausea, and epistaxis. The incidence of grade 3-4 reactions related to defibrotide was 7%, mainly hypotension, pulmonary and gastrointestinal bleeding, and abdominal cramps. Only 4% of patients discontinued treatment due to adverse reactions. In other words, the side effects of defibrotide are usually mild, and patients do not need to worry too much.

Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrotide. These reactions include rash, urticaria, and angioedema. If a severe hypersensitivity reaction occurs, discontinue defibrotide, treat with standard medical care, and monitor until symptoms resolve.

Because the physical condition of each patient is different, if the patient feels that the adverse reactions are relatively strong and unbearable during the use of defibrotide (defiteli), he should stop taking the drug in time and seek medical treatment. The patient should not take the drug blindly.